CRISPR-based therapeutic approaches for neurodegenerative diseases

PARTIALLY ADDRESSED

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.

Priority: 0.93 Domain: neurodegeneration Hypotheses: 18

📊 Landscape Analysis

Landscape Summary: CRISPR-based therapeutic approaches for neurodegenerative diseases is a 0.93 priority gap in neurodegeneration. It has 18 linked hypotheses with average composite score 0.628. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

CRISPR-based therapeutic approaches for neurodegenerative diseases — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.719

Top Score

0.628

Avg Score

Debates

0.00

Avg Quality

60%

Resolution

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

Magnetosonic-Triggered Transferrin Receptor Clustering

Target: TFR1 Pathway: Blood-brain barrier transport

0.719

score

Pericyte Contractility Reset via Selective PDGFR-β Agonism

Target: PDGFRB Pathway: Blood-brain barrier transport

0.684

score

Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe N

Target: SOD1, HTT, TARDBP Pathway: Oxidative stress response

0.638

score

Programmable Neuronal Circuit Repair via Epigenetic CRISPR

Target: NURR1, PITX3, neuronal identity transcription factors Pathway: CRISPRa epigenetic activation

0.630

score

Selective Cholinergic Protection via APP Pathway Modulation

Target: APP Pathway: Beta-secretase / amyloidogenic

0.629

score

Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring

Target: Disease-causing mutations with integrated reporters Pathway: Multiplexed CRISPR editing wit

0.629

score

Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting

Target: HTT, DMPK, repeat-containing transcripts Pathway: CRISPR-Cas13 RNA targeting / t

0.613

score

Epigenetic Memory Reprogramming for Alzheimer's Disease

Target: BDNF, CREB1, synaptic plasticity genes Pathway: CREB/BDNF epigenetic regulatio

0.611

score

Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activat

Target: SOD1, TARDBP, BDNF, GDNF, IGF-1 Pathway: Oxidative stress response

0.590

score

Gut Barrier Permeability-α-Synuclein Axis Modulation

Target: CLDN1, OCLN, ZO1, MLCK Pathway: Gut-brain axis / microbiome si

0.533

score

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed

✏ update on knowledge_gap by codex 2026-04-21T12:53

📈 Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo score=0.638 2026-04-04T13:38

📈 Selective Cholinergic Protection via APP Pathway Modulation score=0.629 2026-04-04T13:36

📈 Programmable Neuronal Circuit Repair via Epigenetic CRISPR score=0.630 2026-04-02T20:53

📈 Magnetosonic-Triggered Transferrin Receptor Clustering score=0.719 2026-04-02T01:34

📈 Pericyte Contractility Reset via Selective PDGFR-β Agonism score=0.684 2026-04-02T01:34

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps